Download Lilly Is 8/1/07

Partnering with Eli Lilly and Company
Lilly at a Glance
Founded in 1876 in Indianapolis, Indiana
$18.71B sales in 2007
40,600 employees worldwide
Operations in 87 countries and sales in
138 countries
Award winning culture:
Fortune magazine “100 best Companies to Work
for”
– Industry Week “100 Best-Managed Companies”
– Science Magazine Best Company for Scientists
– Forbes.com “The 75 most Reputable Companies in
the US”
–
Copyright © 2009 Eli Lilly and Company
2
Lilly Global Presence
Canada: Bioproduct
Analytical R&D
San Diego:
Bioproduct
R&D
United Kingdom:
Neuroscience
Research
China: Drug
Discovery R&D
Japan: ADME
R&D
Indianapolis:
Global R&D HQ
Spain: Medicinal
Chemistry
Singapore: Drug
Discovery and
Biomarker R&D
Copyright © 2009 Eli Lilly and Company
Australia: Drug
Discovery R&D
3
Areas of Strategic Focus
Neuroscience
Musculoskeletal
Oncology
Image and Text Copyright © 2008 Photo Researchers, Inc.
All Rights Reserved.
Endocrine
Cardiovascular
Image and Text Copyright © 2008 Photo Researchers, Inc.
Image and Text Copyright © 2008 Photo Researchers, Inc.
All Rights Reserved.
All Rights Reserved.
Copyright © 2009 Eli Lilly and Company
4
Key Innovation Platforms
BioProducts
Small Molecule
Protein
Peptide
Antibody
Copyright © 2009 Eli Lilly and Company
Antisense
5
Lilly Recombinant Protein Products
Copyright © 2009 Eli Lilly and Company
6
The Lilly Development Teams
Copyright © 2009 Eli Lilly and Company
7
Neuroscience Mission Statement
To improve the lives of people
suffering from psychiatric and
neurological disorders with
innovative therapeutic advances.
Copyright © 2009 Eli Lilly and Company
8
Neuroscience: Areas of Interest
Innovative Molecules and Programs in:
•
•
•
•
•
•
•
•
Schizophrenia
Depression
Anxiety disorders
Bipolar disorders
Sleep disorders
Substance abuse (e.g.. Alcoholism)
Cognitive dysfunction
Alzheimer’s and Parkinson’s disease
– Focused on approaches that affect disease progression or modification
•
Pain
– Neuropathic and inflammatory
•
Migraine
– Prophylaxis and acute treatment
– Non-vasoconstrictive approaches
•
Multiple sclerosis
Copyright © 2009 Eli Lilly and Company
9
Lilly’s Neuroscience Clinical Development
Compounds
Regulatory Review
Olanzapine depot
DA/5-HT2 antagonist
Schizophrenia
NERI IV
Norepinephrine reuptake inhib.
Depression, ADHD
Dirucotide
Immunological Tolerance
Multiple Sclerosis
LY-450139
Gamma-secretase inhibitor
Alzheimer’s Disease
Abeta antibody
Passive immunization
Alzheimer’s Disease
mGlu2/3 agonist
mGlu2/3 agonist
Schizophrenia
LY2624803
5HT-2a ant. / H1 inverse agonist
Insomnia
mGluR3
mGluR3 antagonist
Migraine
GRC-6211
Vanilloid receptor 1 antagonist
Osteoarthritic pain
OPRA II
Opioid receptor antagonist
Alcoholism
iGluR5 antagonist
iGluR5 antagonist
Pain
Formulation
Phase III
Phase II
Phase I
Copyright © 2009 Eli Lilly and Company
10
Technology Needs - Neuroscience
1. Predictive biomarkers of any nature (e.g.,
genetic, proteomics, metabolic, other
biochemical, biological, morphological)
2. Predictive animal models
Copyright © 2009 Eli Lilly and Company
11
Lilly Knows From Experience That
Partnering Supports Future Growth
LY-2599506
LY-517717
Eg5
Prasugrel
MBP-8928
GRC-6211
Teplizumab
Exenatide LAR
'00 ‘01
‘02 ‘03 ‘04
LY-2624803
‘05 ’06 ’07 ‘08
ArxxantTM
ruboxistaurin
LY-450139
NERI IV
enzastaurin
arzoxifene
Copyright © 2009 Eli Lilly and Company
LY-2181308
12
External Innovation at Lilly
Copyright © 2009 Eli Lilly and Company
13